BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 26819502)

  • 1. Is irritable bowel syndrome an infectious disease?
    Thompson JR
    World J Gastroenterol; 2016 Jan; 22(4):1331-4. PubMed ID: 26819502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
    Distrutti E; Monaldi L; Ricci P; Fiorucci S
    World J Gastroenterol; 2016 Feb; 22(7):2219-41. PubMed ID: 26900286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.
    Ghoshal UC; Shukla R; Ghoshal U
    Gut Liver; 2017 Mar; 11(2):196-208. PubMed ID: 28274108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Intestinal Microbiota and Irritable Bowel Syndrome.
    Ringel Y; Ringel-Kulka T
    J Clin Gastroenterol; 2015; 49 Suppl 1():S56-9. PubMed ID: 26447966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial.
    Ghoshal UC; Srivastava D; Misra A; Ghoshal U
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):281-9. PubMed ID: 26731696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the ties between irritable bowel syndrome and intestinal microbiota.
    Hong SN; Rhee PL
    World J Gastroenterol; 2014 Mar; 20(10):2470-81. PubMed ID: 24627584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Irritable Bowel Syndrome, Emotion Regulation, and Gut Microbiota].
    Fukudo S
    Brain Nerve; 2016 Jun; 68(6):607-15. PubMed ID: 27279158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.
    Lee KN; Lee OY
    World J Gastroenterol; 2014 Jul; 20(27):8886-97. PubMed ID: 25083061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal microbiota transplantation for managing irritable bowel syndrome.
    El-Salhy M; Mazzawi T
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):439-445. PubMed ID: 29493330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics.
    Principi N; Cozzali R; Farinelli E; Brusaferro A; Esposito S
    J Infect; 2018 Feb; 76(2):111-120. PubMed ID: 29291933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
    Zhuang X; Tian Z; Luo M; Xiong L
    BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
    Didari T; Mozaffari S; Nikfar S; Abdollahi M
    World J Gastroenterol; 2015 Mar; 21(10):3072-84. PubMed ID: 25780308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?
    Bixquert Jiménez M
    Rev Esp Enferm Dig; 2009 Aug; 101(8):553-64. PubMed ID: 19785495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome.
    Cash BD
    Curr Med Res Opin; 2014 Jul; 30(7):1405-15. PubMed ID: 24666019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota as potential orchestrators of irritable bowel syndrome.
    Bennet SM; Ohman L; Simren M
    Gut Liver; 2015 May; 9(3):318-31. PubMed ID: 25918261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets.
    Dahlqvist G; Piessevaux H
    Acta Gastroenterol Belg; 2011 Sep; 74(3):375-80. PubMed ID: 22103040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.